source
- Pfizer and Amgen target GLP-1 weight-loss market to rival Novo Nordisk and Eli LillyThe STATus Report video hosted by Alex Hogan discusses the growing GLP-1 weight-loss drug market. Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound have been on the market for a few years and are pop…
- Cardiovascular biotech Kardigan raises $400M in IPO, fourth 2026 $400M+ offeringKardigan, a cardiovascular drug startup, priced a $400 million initial public offering on Wednesday, adding to a recent surge in large biotech offerings. The company becomes the fourth biotech in…